Treatment of spit tobacco users with transdermal nicotine system and mint snuff

What Was Tested

This randomized controlled trial paper looks at Therapeutic nicotine (patch, non-peptide).

The purpose of this study was to examine the effects of nicotine patch and mint snuff (a nonnicotine product) on craving, withdrawal symptoms, and treatment outcome.

Why It Was Studied

This study involved a 2 x 2 factorial design, with Active Nicotine Versus Placebo Patch as one of the factors and Mint Snuff Versus No Mint Snuff as the other factor.

Spit tobacco users (N = 402, n = 100-101 in each condition) were randomly assigned to 1 of the 4 treatment conditions for a period of 10 weeks.

Who Took Part

Treatment outcome was measured up to 62 weeks.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

A time span of 62 weeks appears in the methods.

What Was Measured

Topics PubMed links to this paper include Administration, Cutaneous, Combined Modality Therapy, Lamiaceae, Nicotine, Plants, Toxic, Substance Withdrawal Syndrome and Tobacco Use Cessation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) over 62 weeks.

The publication is from 2000 (Journal of consulting and clinical psychology), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.